Last updated: February 13, 2026
What Is the Market Context for NDC 00173-0761?
NDC 00173-0761 corresponds to Xyrem (sodium oxybate), indicated primarily for narcolepsy with cataplexy. It is a central nervous system depressant with a unique mechanism, marketed by Jazz Pharmaceuticals. Xyrem faces limited competition, with its primary market being the North American narcolepsy treatment segment.
Global market size for narcolepsy therapeutics was valued at approximately $150 million in 2022 [1]. Xyrem dominates this niche, capturing over 85% of prescription volume in the U.S. based on IMS health data [2].
How Is the Market Evolving for Sodium Oxybate?
Regulatory landscape: The FDA approved a lower-sodium version, Xywav (calcium, magnesium, potassium, and sodium oxybates), in 2020. Xywav provides an alternative with fewer cardiovascular risks, shifting some prescribing toward this new formulation.
Prescriber and patient trends: The demand for narcolepsy drugs remains stable, with annual growth rates of around 3% [3]. The shift toward formulations with lower sodium content influences Xyrem's sales trajectory.
Competition: Limited to Xywav and generic formulations. As of 2023, no generic sodium oxybate products are approved in the U.S., but patent cliff considerations and potential biosimilar entrants could influence future pricing.
Price Projections for NDC 00173-0761
Current Pricing Snapshot
- Xyrem (Brand): Approximate wholesale acquisition cost (WAC) is $275 per 2.5 grams.
- Average prescribed dose: 4.5 grams per night (~$495), with variations based on patient-specific dosing.
- Insurance coverage: Reimbursement largely through specialty pharmacy channels; copayments vary but average around $200–$300/month for insured patients.
Factors Influencing Future Pricing
- Patent status: Patents on Xyrem expired in 2021, but Jazz Pharmaceuticals maintains exclusivity through patents on formulations and delivery devices. Future patent challenges could lead to generic entry, pressing prices downward.
- Regulatory approvals: The introduction of Xywav diversifies the market. This may suppress the premium on Xyrem, especially among cost-sensitive payers.
- Market penetration: As prescribers become more familiar with elementally similar formulations, pricing power may diminish.
Projected Price Trends (Next 3–5 Years)
| Year |
Price Range (per 2.5g dose) |
Notes |
| 2023 |
$275–$300 |
Stable, barring patent challenges. |
| 2024 |
$275–$275 |
Possible slight decrease with increased generic threat. |
| 2025 |
$250–$275 |
Generic entry likely, pressuring prices downward. |
| 2026 |
$225–$250 |
Full generic market penetration possible in certain regions; price reduction expected. |
Potential Discounting Scenarios
- Price discounts: Insurers may negotiate rebates reducing net prices by 30–50%.
- Biosimilar entry: No biosimilar currently exists. Entry could reduce prices by up to 60%, similar to other CNS therapeutics [4].
Conclusion: Market Outlook and Price Projection Summary
Xyrem's market remains mature with stable demand but faces threats from generics and newer formulations like Xywav. Prices are likely to decline over next few years, especially if patent protections lapse. Wholesale prices could fall by 15–20% annually once generic competition intensifies, with net prices decreasing further due to payer rebates.
Key Takeaways
- Xyrem dominates narcolepsy treatment; annual revenues in the hundreds of millions USD.
- No generics currently, but patent expirations and biosimilar developments pose risks.
- Prices are expected to decline modestly over five years, influenced by generic entry and payer negotiations.
- Lower sodium formulations like Xywav are shifting prescribing habits, influencing Xyrem's market share.
- Reimbursement and rebate strategies significantly affect net pricing.
Frequently Asked Questions
1. When will the patent on Xyrem expire?
The original patents expired in 2021, but exclusivity is maintained through secondary patents and formulation protections until approximately 2025–2027.
2. How does Xywav impact Xyrem sales?
Xywav's lower sodium profile appeals to certain patient populations, capturing a portion of the market and limiting Xyrem's growth potential.
3. What are the barriers to generic sodium oxybate?
Complexity of formulation, patent protections, and regulatory hurdles have delayed generic entry, but upcoming patent cliff could change this.
4. How are reimbursement trends affecting pricing?
High deductibles and rebate negotiations lead to significant price reductions at the provider level, impacting net revenue.
5. Are biosimilars plausible for sodium oxybate?
Biosimilar development is unlikely due to the small market size, formulation complexity, and patent protections, but not impossible as patents expire.
Sources:
[1] MarketWatch, "Narcolepsy Drugs Market," 2022.
[2] IQVIA, Prescription Data, 2022.
[3] Statista, "Growth of Narcolepsy Drugs," 2022.
[4] EvaluatePharma, "Biosimilar Impact," 2022.
